Cargando…

Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence

BACKGROUND AND AIMS: Liver resection combined with postoperative sorafenib to prevent recurrence remains a controversial approach for cases of hepatocellular carcinoma (HCC), especially cases with a high risk of recurrence. This study aimed to investigate the efficacy and safety of liver resection c...

Descripción completa

Detalles Bibliográficos
Autores principales: Lei, Jianyong, Zhong, Jinjing, Hao, Jingcheng, Liu, Zhengni, Zhang, Peng, Wu, Lixue, Yan, Lunan, Zhu, Jinqiang, Zeng, Yong, Li, Bo, Wen, Tianfu, Wang, Wentao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5173159/
https://www.ncbi.nlm.nih.gov/pubmed/26981887
http://dx.doi.org/10.18632/oncotarget.3799
_version_ 1782484276101513216
author Lei, Jianyong
Zhong, Jinjing
Hao, Jingcheng
Liu, Zhengni
Zhang, Peng
Wu, Lixue
Yan, Lunan
Zhu, Jinqiang
Zeng, Yong
Li, Bo
Wen, Tianfu
Wang, Wentao
author_facet Lei, Jianyong
Zhong, Jinjing
Hao, Jingcheng
Liu, Zhengni
Zhang, Peng
Wu, Lixue
Yan, Lunan
Zhu, Jinqiang
Zeng, Yong
Li, Bo
Wen, Tianfu
Wang, Wentao
author_sort Lei, Jianyong
collection PubMed
description BACKGROUND AND AIMS: Liver resection combined with postoperative sorafenib to prevent recurrence remains a controversial approach for cases of hepatocellular carcinoma (HCC), especially cases with a high risk of recurrence. This study aimed to investigate the efficacy and safety of liver resection combined with sorafenib for HCC with a high risk of recurrence. RESULTS: Most of the cases of HCC were caused by hepatitis B virus (HBV) infection (23 cases, 92%). Most of these tumors (21 cases, 84%) were stage III according to the TNM staging system (12 cases with IIIa, 9 cases with IIIb). In the months after hepatic resection, 19 of the 25 cases (76%) were diagnosed with HCC recurrence or metastasis. Based on the tumor histological biomarker grading system, the group with higher expression levels of c-Raf-1 showed significantly longer overall survival than the group with lower expression of c-Raf-1 (P = 0.012). However, the long-term tumor-free survival advantage disappeared (P = 0.061). Univariate and multivariate analyses indicated that higher expression of c-Raf-1 was significantly associated with better overall survival (hazard ratio [HR]: 1.842; 95% confidence interval [CI]: 1.211–2.542; P = 0.031) and tumor-free survival (HR: 1.319; 95% CI: 1.017–1.543; P = 0.046) in HCC patients who underwent radical hepatic resection. PATIENTS AND METHODS: We retrospectively collected 25 HCC cases with a high risk of recurrence who underwent radical liver resection and who took sorafenib postoperatively from Jan 2010 to Dec 2012. Factors that might contribute to tumor recurrence and treatment failure such as clinical factors, tumor features, and molecular biomarkers were included in our analysis. CONCLUSIONS: HCC patients with a high risk of post-hepatic resection recurrence may benefit from postoperative sorafenib administered as an adjuvant therapy, especially in cases with high levels of c-Raf-1 expression on histological examination.
format Online
Article
Text
id pubmed-5173159
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-51731592016-12-23 Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence Lei, Jianyong Zhong, Jinjing Hao, Jingcheng Liu, Zhengni Zhang, Peng Wu, Lixue Yan, Lunan Zhu, Jinqiang Zeng, Yong Li, Bo Wen, Tianfu Wang, Wentao Oncotarget Research Paper BACKGROUND AND AIMS: Liver resection combined with postoperative sorafenib to prevent recurrence remains a controversial approach for cases of hepatocellular carcinoma (HCC), especially cases with a high risk of recurrence. This study aimed to investigate the efficacy and safety of liver resection combined with sorafenib for HCC with a high risk of recurrence. RESULTS: Most of the cases of HCC were caused by hepatitis B virus (HBV) infection (23 cases, 92%). Most of these tumors (21 cases, 84%) were stage III according to the TNM staging system (12 cases with IIIa, 9 cases with IIIb). In the months after hepatic resection, 19 of the 25 cases (76%) were diagnosed with HCC recurrence or metastasis. Based on the tumor histological biomarker grading system, the group with higher expression levels of c-Raf-1 showed significantly longer overall survival than the group with lower expression of c-Raf-1 (P = 0.012). However, the long-term tumor-free survival advantage disappeared (P = 0.061). Univariate and multivariate analyses indicated that higher expression of c-Raf-1 was significantly associated with better overall survival (hazard ratio [HR]: 1.842; 95% confidence interval [CI]: 1.211–2.542; P = 0.031) and tumor-free survival (HR: 1.319; 95% CI: 1.017–1.543; P = 0.046) in HCC patients who underwent radical hepatic resection. PATIENTS AND METHODS: We retrospectively collected 25 HCC cases with a high risk of recurrence who underwent radical liver resection and who took sorafenib postoperatively from Jan 2010 to Dec 2012. Factors that might contribute to tumor recurrence and treatment failure such as clinical factors, tumor features, and molecular biomarkers were included in our analysis. CONCLUSIONS: HCC patients with a high risk of post-hepatic resection recurrence may benefit from postoperative sorafenib administered as an adjuvant therapy, especially in cases with high levels of c-Raf-1 expression on histological examination. Impact Journals LLC 2016-03-13 /pmc/articles/PMC5173159/ /pubmed/26981887 http://dx.doi.org/10.18632/oncotarget.3799 Text en Copyright: © 2016 Jianyong et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Lei, Jianyong
Zhong, Jinjing
Hao, Jingcheng
Liu, Zhengni
Zhang, Peng
Wu, Lixue
Yan, Lunan
Zhu, Jinqiang
Zeng, Yong
Li, Bo
Wen, Tianfu
Wang, Wentao
Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence
title Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence
title_full Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence
title_fullStr Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence
title_full_unstemmed Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence
title_short Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence
title_sort hepatocellular carcinoma cases with high levels of c-raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5173159/
https://www.ncbi.nlm.nih.gov/pubmed/26981887
http://dx.doi.org/10.18632/oncotarget.3799
work_keys_str_mv AT leijianyong hepatocellularcarcinomacaseswithhighlevelsofcraf1expressionmaybenefitfrompostoperativeadjuvantsorafenibafterhepaticresectionevenwithhighriskofrecurrence
AT zhongjinjing hepatocellularcarcinomacaseswithhighlevelsofcraf1expressionmaybenefitfrompostoperativeadjuvantsorafenibafterhepaticresectionevenwithhighriskofrecurrence
AT haojingcheng hepatocellularcarcinomacaseswithhighlevelsofcraf1expressionmaybenefitfrompostoperativeadjuvantsorafenibafterhepaticresectionevenwithhighriskofrecurrence
AT liuzhengni hepatocellularcarcinomacaseswithhighlevelsofcraf1expressionmaybenefitfrompostoperativeadjuvantsorafenibafterhepaticresectionevenwithhighriskofrecurrence
AT zhangpeng hepatocellularcarcinomacaseswithhighlevelsofcraf1expressionmaybenefitfrompostoperativeadjuvantsorafenibafterhepaticresectionevenwithhighriskofrecurrence
AT wulixue hepatocellularcarcinomacaseswithhighlevelsofcraf1expressionmaybenefitfrompostoperativeadjuvantsorafenibafterhepaticresectionevenwithhighriskofrecurrence
AT yanlunan hepatocellularcarcinomacaseswithhighlevelsofcraf1expressionmaybenefitfrompostoperativeadjuvantsorafenibafterhepaticresectionevenwithhighriskofrecurrence
AT zhujinqiang hepatocellularcarcinomacaseswithhighlevelsofcraf1expressionmaybenefitfrompostoperativeadjuvantsorafenibafterhepaticresectionevenwithhighriskofrecurrence
AT zengyong hepatocellularcarcinomacaseswithhighlevelsofcraf1expressionmaybenefitfrompostoperativeadjuvantsorafenibafterhepaticresectionevenwithhighriskofrecurrence
AT libo hepatocellularcarcinomacaseswithhighlevelsofcraf1expressionmaybenefitfrompostoperativeadjuvantsorafenibafterhepaticresectionevenwithhighriskofrecurrence
AT wentianfu hepatocellularcarcinomacaseswithhighlevelsofcraf1expressionmaybenefitfrompostoperativeadjuvantsorafenibafterhepaticresectionevenwithhighriskofrecurrence
AT wangwentao hepatocellularcarcinomacaseswithhighlevelsofcraf1expressionmaybenefitfrompostoperativeadjuvantsorafenibafterhepaticresectionevenwithhighriskofrecurrence